ABC294640

also known as Opaganib · Yeliva

Small molecule targets SPHK2 via inhibition

Developed for: COVID-19 · hilar cholangiocarcinoma · diffuse large B-cell lymphoma · hepatocellular carcinoma · Kaposi's sarcoma · malignant pancreatic neoplasm · plasma cell myeloma · pneumonia
+3 more
· prostate cancer · respiratory tract infectious disorder · Coronaviridae infectious disease
Investigated by: RedHill Biopharma Limited · Apogee Biotechnology Corporation · National Cancer Institute (NCI) · Medical University of South Carolina · Duke University · FDA Office of Orphan Products Development
+1 more
· Louisiana State University Health Sciences Center in New Orleans

Trials 9

today NCT04467840 · Ph 2/3 NCT04502069 · Ph 1/2 NCT04207255 · Ph 2 NCT02939807 · Ph 2 NCT03377179 · Ph 2 NCT02757326 · Ph 1/2 NCT02229981 · Ph 1/2 NCT01488513 · Ph 1

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial · 1 met primary
Phase 1	NCT01488513	Aug 2011 → Aug 2014	malignant pancreatic neoplasm	RedHill Biopharma Limited	Completed	Met primary
Phase 1/23 trials
Phase 1/2	NCT04502069	Aug 2020 → Feb 2021	COVID-19, respiratory tract infectious disorder	RedHill Biopharma Limited	Withdrawn	No outcome recorded
Phase 1/2	NCT02757326	Dec 2016 → May 2019	plasma cell myeloma	RedHill Biopharma Limited	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT02229981	Jul 2014 → Jun 2019	Kaposi's sarcoma, diffuse large B-cell lymphoma	RedHill Biopharma Limited	Withdrawn	No outcome recorded Stop: Enrollment
Phase 23 trials · 1 met primary
Phase 2	NCT04207255	Mar 2020 → Aug 2023	prostate cancer	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT02939807	Sep 2019 → Sep 2023	hepatocellular carcinoma	Medical University of South Carolina	Withdrawn	No outcome recorded
Phase 2	NCT03377179	Mar 2018 → Jun 2022	hilar cholangiocarcinoma	RedHill Biopharma Limited	Completed	Met primary
Phase 2/31 trial · 1 missed
Phase 2/3	NCT04467840	Aug 2020 → Jul 2021	COVID-19, pneumonia	RedHill Biopharma Limited	Completed	Missed primary
Phase not stated1 trial
—	NCT03414489	—	hilar cholangiocarcinoma	RedHill Biopharma Limited	No longer available	No outcome recorded
Comparator or background therapy1 trial
Phase 2	NCT04414618 Comparator	Jul → Nov 2020	Coronaviridae infectious disease	RedHill Biopharma Limited	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 58

Date	Issuer	Release
2026-06-09	RedHill Biopharma Limited	Regulatory RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB).
2026-04-22	RedHill Biopharma Limited	Results RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 redhillbio.com ↗ New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC)
2025-12-15	RedHill Biopharma Limited	Results RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells redhillbio.com ↗ New in vivo study shows adding opaganib, a potent SPHK2 inhibitor, to venetoclax reduces CLL cell (CD19⁺, CD5⁺) counts by 50% compared to controls
2025-04-16	RedHill Biopharma Limited	Results RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption redhillbio.com ↗ Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models
2024-12-10	RedHill Biopharma Limited	Results Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development redhillbio.com ↗
2024-09-03	RedHill Biopharma Limited	Results New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality redhillbio.com ↗
2024-08-26	RedHill Biopharma Limited	Regulatory RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to opaganib for treatment of neuroblastoma, a type of childhood cancer that develops from immature nerve cells and accounts for 15% of all pediatric cancer-related deaths.
2024-08-19	RedHill Biopharma Limited	Results RedHill Announces Positive Obesity and Diabetes Results with Opaganib redhillbio.com ↗
2024-02-20	RedHill Biopharma Limited	Results RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication redhillbio.com ↗
2023-12-20	RedHill Biopharma Limited	Results RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola redhillbio.com ↗
2023-10-03	RedHill Biopharma Limited	Results RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study redhillbio.com ↗
2022-11-17	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury redhillbio.com ↗ Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective impact on hematological and kidney function following total body irradiation (TBI)
2022-11-14	RedHill Biopharma Limited	Results RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published redhillbio.com ↗ Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy
2022-10-03	RedHill Biopharma Limited	Results RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5 redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 (upamostat)1 and twice-daily opaganib2.
2022-07-12	RedHill Biopharma Limited	Results RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences redhillbio.com ↗ Phase 2/3 data demonstrating a 62% reduction in mortality in opaganib-treated patients requiring FiO2 up to 60% to be presented
2022-04-11	RedHill Biopharma Limited	Results RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro redhillbio.com ↗ Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19
2022-02-07	RedHill Biopharma Limited	Results RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 redhillbio.com ↗ The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients.
2022-01-13	RedHill Biopharma Limited	Results RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients redhillbio.com ↗ Treatment with opaganib resulted in viral RNA clearance in a median of 10 days while the median for clearance in the placebo arm was not reached by the end of 14-days treatment for placebo (Hazard Ratio 1.34; nominal p-value=0.043, N=437/463).
2021-10-04	RedHill Biopharma Limited	Results RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients redhillbio.com ↗ 62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm
2021-09-14	RedHill Biopharma Limited	Results RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients redhillbio.com ↗ Preliminary top-line data showed that the study did not meet its primary endpoint.
2021-09-07	RedHill Biopharma Limited	Results RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis redhillbio.com ↗ Results from the study showed that opaganib significantly decreased renal fibrosis.
2021-08-26	RedHill Biopharma Limited	Results RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations.
2021-08-26	RedHill Biopharma Limited	Results RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights redhillbio.com ↗ Primary endpoint met in the ongoing prostate cancer Phase 2 study of opaganib, based on a preliminary review of partial unaudited data; patient accrual, treatment and analysis ongoing
2021-06-28	RedHill Biopharma Limited	Results RedHill Biopharma’s Opaganib Inhibits COVID-19 Variants in Preclinical Study redhillbio.com ↗ today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva®, ABC294640)1.
2021-06-21	RedHill Biopharma Limited	Results RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 redhillbio.com ↗ 50% of patients treated with opaganib (n=22) reached room air by Day 14 compared to 22% in the placebo group (n=18).
2021-01-29	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib1 in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
2020-12-31	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)1 in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.
2020-12-15	RedHill Biopharma Limited	Results RedHill’s Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model redhillbio.com ↗ Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS
2020-10-07	RedHill Biopharma Limited	Results RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review redhillbio.com ↗ Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19
2020-09-22	RedHill Biopharma Limited	Regulatory Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia.
2020-09-08	RedHill Biopharma Limited	Results RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue.
2020-08-27	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy redhillbio.com ↗ The SMC reviewed unblinded safety data from the first 12 patients treated for at least seven days, recommending that the study continue without change.
2020-08-06	RedHill Biopharma Limited	Regulatory RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico redhillbio.com ↗ RedHill’s study has now been approved in Mexico, the UK, and Russia and is under review in Italy, Brazil and additional countries.
2020-07-22	RedHill Biopharma Limited	Regulatory RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico redhillbio.com ↗ Phase 2/3 study process initiated in Brazil and Mexico
2020-07-16	RedHill Biopharma Limited	Regulatory RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced approval from the Ministry of Health of the Russian Federation for its Clinical Trial Authorization (CTA) application for a Phase 2/3 study evaluating opaganib (Yeliva®, ABC294640)1 in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.
2020-06-29	RedHill Biopharma Limited	Regulatory RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK redhillbio.com ↗ This timely approval from the UK regulatory authority for the Phase 2/3 study with opaganib comes as the global infection rates continue to grow and there remains a serious unmet medical need for a safe and effective treatment for COVID-19.
2020-06-24	RedHill Biopharma Limited	Results Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill’s Opaganib Compared to Matched Case-Control Group redhillbio.com ↗ Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital
2020-06-18	RedHill Biopharma Limited	Regulatory RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK redhillbio.com ↗ Following our submission of the Clinical Trial Application in Russia last week, we have submitted similar applications in the UK and Italy, and we are looking to expand the study to additional countries and start treating patients soon.
2020-06-10	RedHill Biopharma Limited	Regulatory RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib redhillbio.com ↗
2020-05-27	RedHill Biopharma Limited	Results RedHill Biopharma Provides Q1/2020 Financial Results and Recent Highlights Including Initial Movantik® Revenues redhillbio.com ↗ The treated patients were all weaned from oxygen and discharged from the hospital on room air, without having to receive mechanical ventilation.
2020-05-08	RedHill Biopharma Limited	Regulatory RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S. redhillbio.com ↗
2020-04-27	RedHill Biopharma Limited	Results Six COVID-19 Patients Treated with RedHills Opaganib Under Compassionate Use Show Objective Clinical Improvement redhillbio.com ↗ Five of the six patients have been weaned from oxygen altogether, the sixth patient continues to improve, and three out of the six were discharged from the hospital
2020-04-17	RedHill Biopharma Limited	Regulatory IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma redhillbio.com ↗ RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study its investigational drug, opaganib (Yeliva®, ABC294640)1, for the treatment of SARS-CoV-2 infection (COVID-19).
2020-04-17	RedHill Biopharma Limited	Results Additional Update on COVID-19 Compassionate Use with Opaganib in Israel Provided by RedHill Biopharma redhillbio.com ↗ All five patients have shown an improved CRP, with four of the five patients also demonstrating measurable clinical improvement, including required supplemental oxygenation and higher lymphocyte counts
2020-04-13	RedHill Biopharma Limited	Results RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel redhillbio.com ↗ Objective improvement in first two patients treated with opaganib in Israel who have demonstrated measurable clinical improvement within days of treatment initiation, including decreased supplemental oxygen requirements, decreased C-reactive protein (CRP) levels and increased lymphocyte levels
2020-04-06	RedHill Biopharma Limited	Regulatory RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use redhillbio.com ↗ The treatment is administered under a compassionate use program in accordance with the Israeli Ministry of Health guidelines, with additional patients expected to be treated in the coming days.
2020-04-06	RedHill Biopharma Limited	Regulatory RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy redhillbio.com ↗
2018-11-14	RedHill Biopharma Limited	Results RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium redhillbio.com ↗ Results from the Phase Ib portion of the study did not show any dose-limiting toxicities.
2018-09-06	RedHill Biopharma Limited	Results RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma redhillbio.com ↗
2017-04-20	RedHill Biopharma Limited	Results RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors redhillbio.com ↗ The Phase I study with YELIVA® in patients with advanced solid tumors successfully met its primary and secondary endpoints
2017-04-04	RedHill Biopharma Limited	Regulatory RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma redhillbio.com ↗
2017-01-06	RedHill Biopharma Limited	Results RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference redhillbio.com ↗ A Phase I study with YELIVA® in patients with advanced solid tumors successfully met its primary and secondary endpoints
2017-01-06	RedHill Biopharma Limited	Results RedHill Announces YELIVA Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference redhillbio.com ↗ Of the three cholangiocarcinoma patients in the Phase I study, one patient had a sustained partial response (Overall Survival (OS) = 20.3 months) and the other two had stable disease (OS = 17.6 and 16.3 months)
2016-11-21	RedHill Biopharma Limited	Results RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium redhillbio.com ↗
2016-06-21	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors redhillbio.com ↗ YELIVA™ was well tolerated over a prolonged period at doses inducing the expected pharmacodynamic effects.
2016-03-10	RedHill Biopharma Limited	Results RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer redhillbio.com ↗ TEL-AVIV, Israel, March 10, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced the publication of an article evaluating the therapeutic potential of YELIVA™ (ABC294640), the Company's orally-administered first-in-class Sphingosine kinase-2 (SK2) selective inhibitor, in the treatment of cholangiocarcinoma (bile duct cancer).
2015-10-26	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Top-line Results from YELIVA™ (ABC294640) Phase I Study in Advanced Solid Tumors redhillbio.com ↗ The Phase I study with YELIVA™ (ABC294640) successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
2015-08-24	RedHill Biopharma Limited	Results RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of ABC294640 (YELIVA(TM)) in Prostate Cancer redhillbio.com ↗ The publication in the peer-reviewed journal Molecular Cancer Research details promising pre-clinical results suggesting ABC294640 significantly inhibits prostate cancer tumor growth

All press releases naming this drug 103 releases

Date	Issuer	Release
Show all 103 releases opens the full record — a long page

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	ABC294640	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02939807 ↗ 4 NCT03377179 ↗ NCT02229981 ↗ NCT03414489 ↗ NCT01488513 ↗
Known as	Opaganib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02757326 ↗ 4 NCT04207255 ↗ NCT04414618 ↗ NCT04502069 ↗ NCT04467840 ↗
Known as	Yeliva	“This program is designed to provide access to ABC294640 (Yeliva ®) for treatment of cholangiocarcinoma (CCA) prior to approval by the local regulatory agency.” NCT03414489 ↗
Action	Inhibit	“sphingosine kinase-2 inhibitor ABC294640” NCT01488513 ↗
Modality	Small molecule	— CHEMBL2158685 ↗
Route	Oral	“Patients receive sphingosine kinase-2 inhibitor ABC294640 orally (PO) twice daily (BID) on days 1-28.” NCT01488513 ↗
Target	SPHK2	“selective SphK2 inhibition” NCT04414618 ↗